PBS attracting smugglers, as Australians pay just a fraction of drug costs

6 November 2006

The export of medicines supplied under Australia's Pharmaceutical Benefits Scheme (PBS) has been illegal since 1999, with the only exemptions being for personal use by tourists and Australian residents who are temporarily overseas. However, numerous reports in local newspapers of seizures of quantities of PBS drugs at airports and from parcels intercepted at post offices, indicate the practice is growing, according to the Marketletter's sources in the country.

The PBS system attracts smugglers because Australians pay only a small proportion of the real cost of taxpayer subsidized medication, while people in many neighboring countries pay the full cost. Smugglers often export the medicines for profit, while others send subsidized drugs to help relatives overseas. Those caught face confiscation of the drugs and a fine.

Medicare/ACS using data mining to stop the illegal trade

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight